Pharmaceutisch Weekblad

, Volume 12, Issue 5, pp 184–187 | Cite as

Comparative bioavailability study of two brands of prazosin-containing tablets in healthy volunteers

  • P. J. M. Guelen
  • T. J. Janssen
  • M. H. Lam
  • T. B. Vree
  • P. S. Exler


The bioavailability of two prazosin formulations was studied in 12 healthy volunteers. 1 Subject left the study. Based on the statistical tests of the pharmacokinetic parameters of prazosin in 11 volunteers, such ast1/2,Cmax,tmax and AUC, it could be concluded that both preparations had comparable bioavailabilities.


Biological availability Clinical trials Pharmacokinetics Prazosin 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Benet LZ, Massoud N, Gambertoglio JG. Pharmacokinetic basis for drug treatment. New York: Raven Press, 1984.Google Scholar
  2. 2.
    Gilman AG, Goodman LS, Gilman A, Red. Goodman and Gilman's The pharmacological basis of therapeutics. 6th ed. New York: MacMillan Publishing Company, 1980:806–7.Google Scholar
  3. 3.
    Hoffman BB. Adrenergic receptor blocking drugs. In: Katzung BG, ed. Basic and clinical pharmacology. Los Altos: Lange Medical Publications, 1984:97–107.Google Scholar
  4. 4.
    Rubin PC, Scott PJW, Reid JL. Prazosin disposition in young and elderly subjects. Br J Clin Pharmacol 1981;12:401–4.Google Scholar
  5. 5.
    Hobbs DC, Twomey TM, Palmer RV. Pharmacokinetics of prazosin in man. J Clin Pharmacol 1978;18:402–6.Google Scholar
  6. 6.
    Jaillon P. Clinical pharmacokinetics of prazosin. Clin Pharmacokinet 1980;5:365–76.Google Scholar
  7. 7.
    Verbesselt R, Mullie A, Tjandramaga TB. The effect of food intake on the plasma kinetics and tolerance of prazosin. Acta Ther 1976;2:27–39.Google Scholar
  8. 8.
    Lin ET, Baughman RA, Benet LZ. High performance liquid chromatographic determination of prazosin in human plasma, whole blood and urine. J Chromatogr 1980;183:367–71.Google Scholar
  9. 9.
    Fluehler H, Grieve AP, Mandallaz D, Mau J, Moser HA. Bayesian approach to bioequivalence assesment: an example. J Pharm Sci 1983;72:1178–81.Google Scholar
  10. 10.
    Hauck WW, Anderson S. A new statistical procedure for testing equivalence in two group comparative bioavailability trials. J Pharmacokinet Biopharm 1984;12:83–91.Google Scholar
  11. 11.
    Rodda BE, Davis RL. Determining the probability of an important difference in bioavailability. Clin Pharmacol Ther 1980;28:247–52.Google Scholar
  12. 12.
    Westlake WJ. Use of confidence intervals in analysis of comparative bioavailability trials. J Pharm Sci 1972;61:1340–1.Google Scholar
  13. 13.
    Westlake WJ. Symmetrical confidence intervals for bioequivalence trials. Biometrics 1976;32:741–4.Google Scholar
  14. 14.
    Baughman RA, Arnold S, Benet LT, Lin ET, Chatterjee K, Williams RL. Altered prazosin pharmacokinetics in congestive heart failure. Eur J Clin Pharmacol 1980;17:425–8.Google Scholar
  15. 15.
    Althuis TH, Hess H-J. Synthesis and identification of the major metabolites of Prazosin formed in dog and rat. J Med Chem 1977;20:146–9.Google Scholar
  16. 16.
    Runkel R, Forchielli E, Boost G, et al. Naproxen metabolism, excretion, and comparative pharmacokinetics. Scand J Rheumatol 1973;2:29–36.Google Scholar
  17. 17.
    Taylor JA, Twomey TM, Schach von Wittenau M. The metabolic fate of Prazosin. Xenobiotica 1977;7:357–64.Google Scholar
  18. 18.
    Antilla M, Haataja M, Kasanen A. Pharmacokinetics of naproxen in subjects with normal and impaired renal function. Eur J Clin Pharmacol 1980;18:263–8.Google Scholar

Copyright information

© Royal Dutch Association for Advancement of Pharmacy 1990

Authors and Affiliations

  • P. J. M. Guelen
    • 1
  • T. J. Janssen
    • 1
  • M. H. Lam
    • 1
  • T. B. Vree
    • 2
  • P. S. Exler
    • 3
  1. 1.Farma Research BVAA Ravensteinthe Netherlands
  2. 2.Department of Clinical PharmacyUniversity Hospital NijmegenHB Nijmegenthe Netherlands
  3. 3.Farmaver BVDJ Zevenaarthe Netherlands

Personalised recommendations